vs
亚玛芬体育（AS）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是亚玛芬体育的1.4倍（$1.5B vs $1.1B），Steris净利率更高（12.9% vs 1.8%，领先11.1%），Steris自由现金流更多（$199.5M vs $92.2M）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
AS vs STE — 直观对比
营收规模更大
STE
是对方的1.4倍
$1.1B
净利率更高
STE
高出11.1%
1.8%
自由现金流更多
STE
多$107.3M
$92.2M
损益表 — Q1 FY2024 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.5B |
| 净利润 | $19.0M | $192.9M |
| 毛利率 | 52.8% | 43.8% |
| 营业利润率 | 12.4% | 18.3% |
| 净利率 | 1.8% | 12.9% |
| 营收同比 | — | 9.2% |
| 净利润同比 | — | 11.2% |
| 每股收益（稀释后） | $0.05 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASSTE
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | $1.1B | $1.1B |
净利润ASSTE
| Q4 25 | — | $192.9M | ||
| Q3 25 | — | $191.9M | ||
| Q2 25 | — | $177.4M | ||
| Q1 25 | — | $145.7M | ||
| Q4 24 | — | $173.5M | ||
| Q3 24 | — | $150.0M | ||
| Q2 24 | — | $145.4M | ||
| Q1 24 | $19.0M | $-1.4M |
毛利率ASSTE
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | 52.8% | 40.2% |
营业利润率ASSTE
| Q4 25 | — | 18.3% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 17.7% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | — | 17.9% | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | 12.4% | 22.0% |
净利率ASSTE
| Q4 25 | — | 12.9% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 12.8% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | — | 11.4% | ||
| Q1 24 | 1.8% | -0.1% |
每股收益（稀释后）ASSTE
| Q4 25 | — | $1.96 | ||
| Q3 25 | — | $1.94 | ||
| Q2 25 | — | $1.79 | ||
| Q1 25 | — | $1.48 | ||
| Q4 24 | — | $1.75 | ||
| Q3 24 | — | $1.51 | ||
| Q2 24 | — | $1.46 | ||
| Q1 24 | $0.05 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | — | $7.2B |
| 总资产 | — | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资ASSTE
| Q4 25 | — | $423.7M | ||
| Q3 25 | — | $319.2M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $171.7M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $172.2M | ||
| Q2 24 | — | $198.3M | ||
| Q1 24 | — | $207.0M |
总债务ASSTE
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益ASSTE
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $6.4B | ||
| Q1 24 | — | $6.3B |
总资产ASSTE
| Q4 25 | — | $10.6B | ||
| Q3 25 | — | $10.4B | ||
| Q2 25 | — | $10.4B | ||
| Q1 25 | — | $10.1B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $10.2B | ||
| Q2 24 | — | $10.1B | ||
| Q1 24 | — | $11.1B |
负债/权益比ASSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $92.2M | $199.5M |
| 自由现金流率自由现金流/营收 | 8.8% | 13.3% |
| 资本支出强度资本支出/营收 | 2.1% | 6.6% |
| 现金转化率经营现金流/净利润 | 6.02× | 1.55× |
| 过去12个月自由现金流最近4个季度 | — | $917.1M |
8季度趋势，按日历期对齐
经营现金流ASSTE
| Q4 25 | — | $298.2M | ||
| Q3 25 | — | $287.8M | ||
| Q2 25 | — | $420.0M | ||
| Q1 25 | — | $260.8M | ||
| Q4 24 | — | $332.8M | ||
| Q3 24 | — | $250.7M | ||
| Q2 24 | — | $303.7M | ||
| Q1 24 | $114.3M | $254.8M |
自由现金流ASSTE
| Q4 25 | — | $199.5M | ||
| Q3 25 | — | $201.3M | ||
| Q2 25 | — | $326.4M | ||
| Q1 25 | — | $189.9M | ||
| Q4 24 | — | $243.6M | ||
| Q3 24 | — | $148.8M | ||
| Q2 24 | — | $195.7M | ||
| Q1 24 | $92.2M | $163.3M |
自由现金流率ASSTE
| Q4 25 | — | 13.3% | ||
| Q3 25 | — | 13.8% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 15.3% | ||
| Q1 24 | 8.8% | 14.6% |
资本支出强度ASSTE
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 7.7% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | 2.1% | 8.2% |
现金转化率ASSTE
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | 1.50× | ||
| Q2 25 | — | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | 6.02× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
